RE-LY
2009
Randomized Evaluation of Long-term Anticoagulation Therapy
In 18,113 patients with non-valvular AF, dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin, with similar major bleeding.
Result
Efficacy: Stroke or systemic embolismRR 0.66
Below 1 favours dabigatran 150 mg twice daily, above 1 favours warfarin.
Event rates Dabigatran 150 mg twice daily 1.11% vs warfarin 1.69% per year
Also reported: 110 mg dose non-inferior with less bleed.
- Subtopic
- Anticoagulation
- Design
- Open-label (PROBE), 2 yr
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Connolly SJ, et al. N Engl J Med. 2009;361(12):1139-1151.doi 10.1056/NEJMoa0905561
Discussion & critique
First NOAC win. Open-label design and dyspepsia signal. Renal clearance is dominant: avoid in CrCl < 30.